Gracell Biotechnologies Inc. (GRCL) has a consensus analyst rating of Hold, based on 8 analysts covering the stock. Of those, 3 recommend buying, 5 recommend holding, and 0 recommend selling.
The analyst consensus price target for GRCL is $6.00, representing a -41.5% downside from the current price of $10.25. Price targets range from a low of $6.00 to a high of $6.00.
